Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
| Status: | Completed |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 16 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | September 2008 |
| End Date: | December 2012 |
Phase II Trial of Tacrolimus and Rapamycin vs. Tacrolimus and Methotrexate as GVHD Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
The purpose of this research is to compare the effectiveness of Tacrolimus and Rapamycin to
Tacrolimus and Methotrexate in the prevention of severe graft-versus-host-disease.
Graft-versus-host-disease (GVHD) is a risk associated with allogeneic hematopoietic cell
transplants (HCT). An allogeneic hematopoietic cell transplant is a transplant using bone
marrow and blood cells that come from someone other than the patient (a donor).
Tacrolimus and Methotrexate in the prevention of severe graft-versus-host-disease.
Graft-versus-host-disease (GVHD) is a risk associated with allogeneic hematopoietic cell
transplants (HCT). An allogeneic hematopoietic cell transplant is a transplant using bone
marrow and blood cells that come from someone other than the patient (a donor).
All drugs used in this study have been used in the prevention of graft-versus-host-disease
after allogeneic hematopoietic cell transplant. Tacrolimus and Methotrexate used in
combination are currently used as standard of care in the prevention of
graft-versus-host-disease after allogeneic hematopoietic cell transplant. Tacrolimus and
Rapamycin is a newer combination we are testing to see if it would be better than Tacrolimus
and Methotrexate.
after allogeneic hematopoietic cell transplant. Tacrolimus and Methotrexate used in
combination are currently used as standard of care in the prevention of
graft-versus-host-disease after allogeneic hematopoietic cell transplant. Tacrolimus and
Rapamycin is a newer combination we are testing to see if it would be better than Tacrolimus
and Methotrexate.
Inclusion Criteria:
- Age ≥ 16 and ≤ 70
- Signed informed consent
- Adequate vital organ function
- No active infection, or asymptomatic infection well controlled by antibiotic HIV
negative by ELISA or RT-PCR [if ELISA is positive and RT-PCR is negative, the ELISA
is considered false positive]
- Hepatitis B and C negative by serology or RT-PCR
- Performance status: Karnofsky Performance Status Score ≥ 60%.
Exclusion Criteria:
- Those with any Sorror's co-morbidity factors with score > 3
- 2 or more Sorror's factors with composite score of ≥ 3
We found this trial at
1
site
Click here to add this to my saved trials
